Drug Trial Radar · NCT07932496
A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies.
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Nov 9, 2026
Primary completion
Oct 15, 2029
Study completion Oct 15, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CT204V-CD19 × CD20, a dual targeting in vivo gene therapy generating anti-CD19/CD20 CAR-T cells in participants with R/R B-cell malignancies.
Conditions
- Relapsed or Refractory B-Cell Malignancies
Interventions
CT204V-CD19 × CD20Drug
Experimental
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse Events(AEs)/Serious Adverse Events (SAEs), Phase 1 of the study.Time frame: Up to 15 years
- Number of Dose-Limiting Toxicities (DLTs) events during dose escalation, Phase 1 of the study.Time frame: Up to 28 days.
- Number of AEs leading to dose reduction, withdrawal, interruption, Phase 1 of the study.Time frame: Up to 1 year.
- Number of AEs leading to death, Phase 1 of the study.Time frame: Up to 15 years
- Number of AESI (adverse events of special interest), Phase 1 of the study.Time frame: Up to 15 years
- Objective Response Rate (Complete Response+Partial Response) per Lugano Classification, Phase 2 of the study.Time frame: Up to 24 months.
- Complete Response (CR) rate, Phase 2 of the study.Time frame: Up to 24 months.
- Best Overall Response (BOR), Phase 2 of the study.Time frame: Up to 24 months.
- Duration of Response (DoR), Phase 2 of the study.Time frame: Up to 24 months.
- Duration of Complete Response (DoCR), Phase 2 of the study.Time frame: Up to 24 months.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.